LGALS9 and malignant colon neoplasm: Anti-Gal-9 antibody in combination with an agonist antibody to the T cell co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor-related protein) significantly outperforms monotherapy with either agent in suppressing tumor growth and improving survival in the mouse models of colon cancer and TNBC 8.